Thromb Haemost 1991; 65(03): 291-295
DOI: 10.1055/s-0038-1648137
Original Article
Schattauer GmbH Stuttgart

Fibrinolysis and Coagulation in Patients with Infectious Disease and Sepsis

J Philippé
*   The Department of Clinical Chemistry, Coagulation Laboratory, University Hospital of Gent, Belgium
,
F Offner
**   The Department of Intensive Care Medicine, University Hospital of Gent, Belgium
,
P J Declerck
***   The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
G Leroux-Roels
*   The Department of Clinical Chemistry, Coagulation Laboratory, University Hospital of Gent, Belgium
,
D Vogelaers
**   The Department of Intensive Care Medicine, University Hospital of Gent, Belgium
,
G Baele
*   The Department of Clinical Chemistry, Coagulation Laboratory, University Hospital of Gent, Belgium
,
D Collen
***   The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received: 06 April 1990

Accepted after revision 08 November 1990

Publication Date:
02 July 2018 (online)

Summary

Sepsis is often associated with hemostatic dysfunction. This study aimed to relate changes in fibrinolysis and coagulation parameters to sepsis and sepsis outcome. Urokinase-type plasminogen activator (u-PA) antigen, tissue-type plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor (PAI) type 1 antigen, PAI activity, antithrombin (AT) III activity, and protein C activity were measured in 24 patients suffering from sepsis or septic shock and the results were compared with those observed in 30 non-sepsis patients with severe infectious disease. The u-PA level was markedly increased in plasma of sepsis patients as compared to non-sepsis patients (11.5 ± 9.4 versus 1.6 ± 1.5 ng/ml, p <0.0001). PAI-1 antigen and t-PA activity showed a significant increase in sepsis patients (320 ± 390 ng/ml versus 120 ± 200 ng/ml, and 3.0 ± 3.6 IU/ml versus 1.0 ± 0.7 IU/ml, respectively, p <0.01). AT III was decreased in sepsis patients (58 ± 28% in sepsis versus 79 ± 26% in severe infectious disease, p <0.01) as was protein C (30 ± 18% versus 58 ± 27%, p <0.001). No significant difference was found for t-PA antigen nor for PAI activity. Nonsurvivors of sepsis were distinguished mainly by a high u-PA antigen level and increased t-PA activity. It is concluded that plasma u-PA antigen showed the strongest significant difference, among the parameters evaluated, between sepsis and severe infection. u-PA antigen may be of prognostic value in patients admitted to the medical intensive care unit for severe infectious disease.

 
  • REFERENCES

  • 1 Sanford JP. Epidemiology and overview of the problem. In: Septic Shock Root RK, Sande MA. (eds). Churchill Livingstone; New York: 1985: 1-11
  • 2 Cronberg S, Skansberg P, Nivenios-Larsson K. Disseminated intravascular coagulation in septicaemia caused by beta-hemolytic streptococci. Thromb Res 1973; 3: 405-411
  • 3 Bick RL. Disseminated intravascular coagulation and related syndromes: A clinical review. Semin Thromb Hemostas 1988; 14: 299-338
  • 4 Morrison DC, Kline LF. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol 1977; 118: 362-368
  • 5 Levin J, ten Cate JW, Büller HR, van Deventer SJ, Sturk A. (eds). Bacterial Endotoxins. Pathophysiological Effects, Clinical Significance, and Pharmacological Control. Alan R Liss; New York: 1988
  • 6 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-1172
  • 7 Pralong G, Calandra T, Glauser M-P, Schellekens J, Verhoef J, Bachmann F, Kruithof EKO. Plasminogen activator inhibitor 1: A new prognostic marker in septic shock. Thromb Haemostas 1989; 61: 459-462
  • 8 Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
  • 9 Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathologic conditions. Thromb Res 1984; 33: 523-530
  • 10 Kruithof EKO, Tran-Thang C, Bachmann F. The fast acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemostas 1986; 55: 65-69
  • 11 Erickson LA, Hekman CM, Loskutoff DJ. The primary plasminogen activator inhibitors in endothelial cells, platelets, serum and plasma are immunologically related. Proc Natl Acad Sci USA 1985; 82: 8710-8714
  • 12 Kirchheimer JC, Huber K, Polterauer P, Binder BR. Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma. Thromb Haemostas 1985; 54: 617-618
  • 13 Grondahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, Dombemowsky P, Dano K. Sensitive and specific enzyrne-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 1988; 111: 42-51
  • 14 Mannucci PM, Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet 1982; 2: 463-467
  • 15 Griffin JH, Mosher DF, Zimmerman TS, Kleiss AJ. Protein C, an antithrombotic protein is reduced in hospitalised patients with intravascular coagulation. Blood 1982; 60: 261-264
  • 16 Triantaphyllopoulos DC. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb Haemostas 1984; 51: 232-235
  • 17 Takahashi H, Takakuwa E, Yoshino N, Hanano M, Shibata A. Protein C levels in disseminated intravascular coagulation and thrombotic thrombocytopenic purpura: Its correlation with other coagulation parameters. Thromb Haemostas 1985; 54: 445-449
  • 18 Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985; 66: 59-63
  • 19 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352
  • 20 Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. the methylprednisolone severe sepsis study group. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987 317. 653-658
  • 21 Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-828
  • 22 Darras V, Thienpont M, Stump DC, Collen D. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemostas 1986; 56: 411-414
  • 23 Declerck PJ, Lijnen HR, Verstreken M, Moreau H, Collen D. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis in the single-chain urokinase-type plasminogen activator (u-PA) in plasma. Blood 1990 75. 1794-1800
  • 24 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
  • 25 Declerck PJ, Alessi M-C, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
  • 26 Binnema DJ, van Iersel JJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986; 43: 569-577
  • 27 Collen D, De Cock F, Lijnen HR. Biological and thrombotic properties of proenzyme and active forms of human urokinase - II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemostas 1984 52. 24-26
  • 28 Wojta J, Hoover RL, Daniel TO. Vascular origin determines plasminogen activator expression in human endothelial cells. Renal endothelial cells produce large amounts of single chain urokinase type plasminogen activator. J Biol Chem 1989; 264: 2846-2852
  • 29 Levi M, ten Cate JW, Dooijewaard G, Sturk A, Brommer EJP, Agnelli G. DDAVP induces systemic release of urokinase-type plasminogen activator. Thromb Haemostas 1989; 62: 686-689
  • 30 Unkeless JC, Gordon S, Reich E. Secretion of plasminogen activator by stimulated macrophages. J Exp Med 1974; 139: 834-850
  • 31 Booyse FM, Scheinbuks J, Hua Lin P, Traylor M, Bruce R. Isolation and interrelationships of the multiple molecular tissue-type and urokinase-type plasminogen activator forms produced by cultured human umbilical vein endothelial cells. J Biol Chem 1988; 263: 15129-15138
  • 32 Wun TC, Capuano A. Spontaneous fibrinolysis in whole human plasma. Identification of tissue activator-related protein as the major plasminogen activator causing spontaneous activity in vitro. J Biol Chem 1985 260. 5061-5066
  • 33 Salo T, Liotta LA, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggva-son K. Secretion of basement membrane collagen enzyme and plasminogen activator by transformed cells - Role in metastasis. Int J Cancer 1982; 30: 669-673
  • 34 Quigley JP, Gold L, Schwimmer R, Sullivan LM. Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc Natl Acad Sci 1987; 84: 2776-2780
  • 35 Vassalli J-D, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86-92
  • 36 Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 1031: 2411-2420
  • 37 Del Rosso M, Dini G, Fibbi G. Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts. Cancer Res 1985; 45: 630-636
  • 38 Booyse FM, Lin PH, Traylor M, Bruce R. Purification and properties of a single-chain urokinase-type plasminogen activator form produced by subcultured human umbilical vein endothelial cells. J Biol Chem 1988; 263: 15139-15145
  • 39 Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-1266
  • 40 Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987; 109: 97-104
  • 41 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen activator: role of fibrin. J Biol Chem 1982; 257: 2912-2919
  • 42 Gelehrter TD, Snyder-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165-169
  • 43 Walker FJ. Regulation of activated protein C by a new protein: a possible function for bovine proteinS. J Biol Chem 1980; 255: 5521-5524
  • 44 Si’ P, Letrenne E, Caranobe C, Genestal M, Cathala B, Boneu B. Factor II related antigen and antithrombin III as indicators of liver failure in consumption coagulopathy. Thromb Haemostas 1982; 47: 218-220
  • 45 Rodighiero F, Mannucci PM, Vigano S, Barbui T, Gugliotta L, Cortellaro M, Dini E. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood 1984; 63: 965-969
  • 46 Bick RL, Bick MD, Fekete LF. Antithrombin III patterns in disseminated intravascular coagulation. Am J Clin Pathol 1978; 73: 577-583
  • 47 Takahashi H, Takakuwa E, Yoshino N, Hanano M, Shibata A. Protein C levels in disseminated intravascular coagulation and thrombotic thrombocytopenic purpura: Its correlation with other coagulation parameters. Thromb Haemostas 1985; 54: 445-449
  • 48 Hesselvik JF, Blombäck M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17: 724-733